scPharmaceuticals: FDA Approves Expanded Use of FUROSIX for Edema in CKD Patients
The FDA approved scPharmaceuticals’ supplemental New Drug Application for FUROSCIX, expanding its use to treat edema in adults with...
Chemomab’s Nebakitug Shows Promise in Systemic Sclerosis Treatment
Chemomab Therapeutics announced new scientific data supporting the potential of nebokitug (CM-101) as a novel treatment for systemic sclerosis...
Medicus Pharma: Positive Interim Analysis of SKNJC-003 in BCC Treatment
Medicus Pharma (NASDAQ: MDCX) announced positive interim results from its Phase 2 clinical study of SKNJCT-003, a non-invasive treatment...
Clearside Biomedical CLS-AX Phase 3 Wet AMD Trial Announced
Clearside Biomedical announced positive results from a meeting with the FDA regarding its Phase 3 clinical trial plans for...
Rhenium Obisbemeda Gets FDA Orphan Drug Designation
Plus Therapeutics received Orphan Drug Designation from the FDA for its Rhenium (¹⁸⁶Re) Obisbemeda, a treatment for leptomeningeal metastases...
Sernova Secures $1M Convertible Debt Financing
Sernova Biotherapeutics secured a CAD$1,000,000 convertible debenture financing from existing shareholder and board member, Dr. Steven Sangha. The proceeds...
Journey Medical’s Emrosi™ Rosacea Trial Results Published in JAMA Dermatology
Journey Medical Corporation announced positive Phase 3 trial results for its rosacea treatment, Emrosi (DFD-29), published in JAMA Dermatology....
Vaxart’s Oral Norovirus Vaccine Shows Promise in Elderly Adults
Vaxart, Inc. announced complete data from a Phase 1b trial of its oral norovirus vaccine candidate in older adults,...
Tenax Advances Oral Levosimendan in Phase 3 PH-HFpEF Studies
Tenax Therapeutics announced the FDA’s acceptance of an amendment to expand its Phase 3 LEVEL study for TNX-103 (oral...
Silexion Therapeutics Reports Positive Initial Data from Sil204 in Pancreatic Cancer Models
Silexion Therapeutics (NASDAQ: SLXN) has released positive preclinical data for SIL204, its RNAi therapy targeting KRAS-driven cancers. The study...